Abstract
Metastatic melanoma is a very aggressive cancer. Dacarbazine has been considered as the standard therapy for decades. Due to a better understanding of melanoma cells signalling and immunological response, new targeted therapies are now proposed. The efficency of these new drugs needs to be confirmed by on larger clinical trials. Ipilimumab (anti-CTLA4 monoclonal antibody) and V600-E- B-raf inhibitor have shown encouraging results, while c-KIT and MEK inhibitors are currently under evaluation. These recently published data shed the light on melanoma management. We review here the latest development of these molecules and the current perspectives in the treatment of metastatic melanoma.
Keywords: Melanoma, targeted therapy, ipilimumab, c-KIT inhibitor, B-raf inhibitor
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?
Volume: 10 Issue: 9
Author(s): Fanny Julia, Luc Thomas, Charles Dumontet and Stephane Dalle
Affiliation:
Keywords: Melanoma, targeted therapy, ipilimumab, c-KIT inhibitor, B-raf inhibitor
Abstract: Metastatic melanoma is a very aggressive cancer. Dacarbazine has been considered as the standard therapy for decades. Due to a better understanding of melanoma cells signalling and immunological response, new targeted therapies are now proposed. The efficency of these new drugs needs to be confirmed by on larger clinical trials. Ipilimumab (anti-CTLA4 monoclonal antibody) and V600-E- B-raf inhibitor have shown encouraging results, while c-KIT and MEK inhibitors are currently under evaluation. These recently published data shed the light on melanoma management. We review here the latest development of these molecules and the current perspectives in the treatment of metastatic melanoma.
Export Options
About this article
Cite this article as:
Julia Fanny, Thomas Luc, Dumontet Charles and Dalle Stephane, Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (9) . https://dx.doi.org/10.2174/187152010794479834
DOI https://dx.doi.org/10.2174/187152010794479834 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives
Clinical Cancer Drugs Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry for Biomarker Discovery in Cutaneous Melanoma
Current Proteomics Progress in Nutritional and Health Profile of Milk and Dairy Products: A Novel Drug Target
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations
Current Medicinal Chemistry Epidermal Stem Cells - Role in Normal, Wounded and Pathological Psoriatic and Cancer Skin
Current Stem Cell Research & Therapy Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer
Recent Patents on Biotechnology Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues
Current Drug Metabolism Soy Protein Remnants Digested by Gastro-duodenal Proteases can Alter Microbial Interactions and Intestinal Cholesterol Absorption
Current Proteomics The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines
Current Medicinal Chemistry The HOX Gene Network as a Potential Target for Cancer Therapy
Current Cancer Therapy Reviews Chlorophytum borivilianum: A White Gold for Biopharmaceuticals and Neutraceuticals
Current Pharmaceutical Biotechnology Targeting Aldose Reductase for the Treatment of Cancer
Current Cancer Drug Targets Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis
Current Pharmaceutical Design Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging
Current Molecular Imaging (Discontinued) Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Current Medicinal Chemistry Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets